Cargando…

Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients

Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account. Aim: To assess the influence of the coadministration of CBZ with other AED on the trough plasmatic concentration (C0) of CBZ in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaies, Emna, Zgolli, Fatma, Charfi, Rim, Ben Sassi, Mouna, EL Jebari, Hanene, Salouage, Issam, Daghfous, Riadh, Trabelsi, Sameh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tunisian Society of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003587/
https://www.ncbi.nlm.nih.gov/pubmed/35261014
_version_ 1784686163250905088
author Gaies, Emna
Zgolli, Fatma
Charfi, Rim
Ben Sassi, Mouna
EL Jebari, Hanene
Salouage, Issam
Daghfous, Riadh
Trabelsi, Sameh
author_facet Gaies, Emna
Zgolli, Fatma
Charfi, Rim
Ben Sassi, Mouna
EL Jebari, Hanene
Salouage, Issam
Daghfous, Riadh
Trabelsi, Sameh
author_sort Gaies, Emna
collection PubMed
description Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account. Aim: To assess the influence of the coadministration of CBZ with other AED on the trough plasmatic concentration (C0) of CBZ in epileptic adults. Methods: We performed a retrospective study over a period of 9 years in the Department of Clinical Pharmacology in the Tunisian National Centre “Chalbi Belkahia” of Pharmacovigilance. Our study included samples from adult patients receiving CBZ alone or associated to other AED for epilepsy. Trough plasma CBZ plasma concentrations were measured by an immunological method. Included samples were divided in four groups: i/ group 1 (G1) receiving CBZ as monotherapy, ii/ group 2 (G2) treated by CBZ with an enzyme inducer (phenobarbital or phenytoin), iii/ group 3 (G3) taking CBZ associated to an enzyme inhibitor (valproic acid (VPA)), iv/ group 4 (G4), treated by CBZ associated to enzyme inducer (phenobarbital or phenytoin) and enzyme inhibitor (valproic acid) at the same time. Results: There were no significant differences between different groups in age, weight and sex ratio. However statistical analysis showed a significant decrease in C0/D CBZ ratio between G1 and G2 and between G1 and G4 (p<0.001). However, the difference was not significant between G1 and G3 (p=1.2044). Conclusion: It is important to check and to prevent the consequences of the interaction between CBZ and other AED in order to avoid inefficiency and toxicity.
format Online
Article
Text
id pubmed-9003587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Tunisian Society of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-90035872022-04-15 Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients Gaies, Emna Zgolli, Fatma Charfi, Rim Ben Sassi, Mouna EL Jebari, Hanene Salouage, Issam Daghfous, Riadh Trabelsi, Sameh Tunis Med Article Introduction: Carbamazepine could be used on monotherapy or associated to other antiepileptic drugs (AED). In these cases, drug interactions should be taken into account. Aim: To assess the influence of the coadministration of CBZ with other AED on the trough plasmatic concentration (C0) of CBZ in epileptic adults. Methods: We performed a retrospective study over a period of 9 years in the Department of Clinical Pharmacology in the Tunisian National Centre “Chalbi Belkahia” of Pharmacovigilance. Our study included samples from adult patients receiving CBZ alone or associated to other AED for epilepsy. Trough plasma CBZ plasma concentrations were measured by an immunological method. Included samples were divided in four groups: i/ group 1 (G1) receiving CBZ as monotherapy, ii/ group 2 (G2) treated by CBZ with an enzyme inducer (phenobarbital or phenytoin), iii/ group 3 (G3) taking CBZ associated to an enzyme inhibitor (valproic acid (VPA)), iv/ group 4 (G4), treated by CBZ associated to enzyme inducer (phenobarbital or phenytoin) and enzyme inhibitor (valproic acid) at the same time. Results: There were no significant differences between different groups in age, weight and sex ratio. However statistical analysis showed a significant decrease in C0/D CBZ ratio between G1 and G2 and between G1 and G4 (p<0.001). However, the difference was not significant between G1 and G3 (p=1.2044). Conclusion: It is important to check and to prevent the consequences of the interaction between CBZ and other AED in order to avoid inefficiency and toxicity. Tunisian Society of Medical Sciences 2021-08 2021-08-01 /pmc/articles/PMC9003587/ /pubmed/35261014 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Article
Gaies, Emna
Zgolli, Fatma
Charfi, Rim
Ben Sassi, Mouna
EL Jebari, Hanene
Salouage, Issam
Daghfous, Riadh
Trabelsi, Sameh
Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients
title Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients
title_full Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients
title_fullStr Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients
title_full_unstemmed Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients
title_short Drug interaction between carbamazepine and other antiepileptic drugs in Tunisian epileptic patients
title_sort drug interaction between carbamazepine and other antiepileptic drugs in tunisian epileptic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003587/
https://www.ncbi.nlm.nih.gov/pubmed/35261014
work_keys_str_mv AT gaiesemna druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients
AT zgollifatma druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients
AT charfirim druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients
AT bensassimouna druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients
AT eljebarihanene druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients
AT salouageissam druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients
AT daghfousriadh druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients
AT trabelsisameh druginteractionbetweencarbamazepineandotherantiepilepticdrugsintunisianepilepticpatients